Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 2
Journal homepage
240
Views
1
CrossRef citations to date
0
Altmetric
Connective Tissue Diseases and Related Disorders

Safety and effectiveness of adalimumab in Japanese patients with juvenile idiopathic arthritis: Results from a real-world postmarketing study

Syuji Takeia Department of Pediatrics, Kagoshima University, Kagoshima, JapanCorrespondence[email protected], [email protected]
View further author information
,
Naomi Iwatab Aichi Children’s Health and Medical Center, Obu, Aichi, JapanView further author information
,
Ichiro Kobayashic Hokkaido University, Sapporo, Hokkaido, JapanView further author information
,
Toru Igarashid Department of Pediatrics, Nippon Medical School, Tokyo, JapanView further author information
,
Yoko Yoshinagae AbbVie GK, Tokyo, JapanView further author information
,
Naoko Matsubarae AbbVie GK, Tokyo, JapanView further author information
,
Naomi Sunagae AbbVie GK, Tokyo, JapanView further author information
,
Ayumi Itoe AbbVie GK, Tokyo, JapanView further author information
&
Shumpei Yokotaf Fuji Toranomon Orthopedic Hospital, Gotemba, Shizuoka, JapanView further author information
 show all
Pages 421-430 | Received 29 Jan 2020, Accepted 08 Apr 2020, Published online: 18 May 2020

References

  • Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767–78.
  • Petty RE, Laxer RM, Lindsley CB, Weddernburn LR, Textbook of pediatric rheumatology. 7th ed. Philadelphia: Elsevier; 2016.
  • Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007). Mod Rheumatol. 2007;17(5):353–63.
  • Practice handbook for juvenile idiopathic arthritis 2017 (in Japanese). Japan: Pediatric Standing Committee of the Japan College of Rheumatology, in collaboration with the Pediatric Rheumatology Association of Japan; 2017.
  • Petty RE, International League of Associations for Rheumatology, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390–2.
  • Okamoto N, Yokota S, Takei S, Okura Y, Kubota T, Shimizu M, et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018. Mod Rheumatol. 2019;29(1):41–59.
  • Lorenz HM. Technology evaluation: adalimumab, Abbott laboratories. Curr Opin Mol Ther. 2002;4(2):185–90.
  • Pharmaceuticals and Medical Devices Agency, Japan. Humira Package Insert (in Japanese). Available from: http://www.info.pmda.go.jp/go/pack/3999426G3027_1_01/ [last accessed 2019 Nov 14].
  • Pharmaceuticals and Medical Devices Agency, Japan. Products approved in FY 2011: new drugs; [Humira approval for JIA]. Available from: https://www.pmda.go.jp/files/000229075.pdf [last accessed 2019 Nov 14].
  • Yokota S, Imagawa T, Murata T, Tomiita M, Itoh Y, Fujikawa S, et al. Guidance on the use of adalimumab for juvenile idiopathic arthritis in Japan. Mod Rheumatol. 2012;22(4):491–7.
  • Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–20.
  • Imagawa T, Takei S, Umebayashi H, Yamaguchi K, Itoh Y, Kawai T, et al. Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan. Clin Rheumatol. 2012;31(12):1713–21.
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, et al. Safety of adalimumab in pediatric patients with polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, and Crohn’s disease. J Pediatr. 2018;201:166–75.
  • Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72(4):517–24.
  • Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: The German Biologics JIA Registry. Arthritis Rheumatol. 2014;66(9):2580–9.
  • Ogata H, Watanabe M, Matsui T, Hase H, Okayasu M, Tsuchiya T, et al. Safety of adalimumab and predictors of adverse events in 1693 Japanese patients with Crohn’s disease. J Crohns Colitis. 2016;10(9):1033–41.
  • Takei S. Juvenile idiopathic arthritis. Nihon Rinsho. 2014;72:399–403.
  • Russo RA, Katsicas MM. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol. 2009;36(5):1078–82.
  • Shenoi S, Wallace CA. Diagnosis and treatment of systemic juvenile idiopathic arthritis. J Pediatr. 2016;177:19–26.
  • Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40(2):101–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.